Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplification

Area of Science:

• Genomics
• Cancer Biology
• Molecular Oncology

Background:

• The International Cancer Genome Consortium - Pan-Cancer Analysis of Whole Genomes (ICGC-PCAWG) identified recurrent focal deletions in the BRD4 gene.
• These deletions lead to decreased BRD4 expression despite increased gene copy number, particularly in breast, ovarian, and endometrial cancers.

Purpose of the Study:

• To investigate the role of BRD4 focal deletions in cancer progression.
• To understand how these deletions affect BRD4 gene expression and its isoforms.
• To explore the therapeutic potential of targeting BRD4 levels in cancer.

Main Methods:

• Analysis of open reading frame screen data to assess the impact of BRD4 isoform overexpression on cell growth.
• CRISPR-Cas9 technology to mimic BRD4 focal deletions in ovarian cancer cells.
• Evaluation of tumor growth in OVSAHO ovarian cancer cells with BRD4 isoform overexpression.

Main Results:

• BRD4 focal deletions occur alongside cyclin E1 amplification in multiple cancer types.
• Overexpression of BRD4 long (BRD4-L) and short (BRD4-S(a)) isoforms impairs cell growth and reduces tumor growth in ovarian cancer models.
• Mimicking BRD4 focal deletions using CRISPR-Cas9 rescues cells from BRD4 overexpression toxicity, indicating a need for fine-tuned BRD4 levels.

Conclusions:

• BRD4 focal deletions represent a novel mechanism in cancer progression by disrupting regulatory regions and gene expression.
• Fine-tuning of BRD4 levels is critical for cancer cell proliferation, offering potential therapeutic strategies.
• This study provides the first experimental evidence for a recurrent deletion that reduces toxicity in cancer.